Status and phase
Conditions
Treatments
About
The purpose of this study is to determine whether vincristine sulfate liposome could reduce less peripheral neuropathy than vincristine sulfate,and be as effective as vincristine sulfate in adults with Naïve Acute Lymphoblastic Leukemia.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
De novo untreated ALL patients diagnosed by the bone marrow morphology, immunophenotype.
65 ≥ Age (years) ≥ 18 , male or female,
ECOG Performance status of 0, 1, or 2.
Patients must fulfill the following laboratory values
Didn't receive any of the following treatments within 4 weeks before inclusion: chemotherapy, radiotherapy, replacement therapy, operation, long term of glucocorticoid therapy(>5 days).
No neurological disorders, no nerve or muscle injury (motor and sensory nerve).
Patient must sign the informed consent and obey the protocol.
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
480 participants in 2 patient groups
Loading...
Central trial contact
Yingchang Mi, Doctor
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal